Stock listing

BMV:VRTX Vertex Pharmaceuticals Incorporated Acciones

Mexican listing (BMV) of Vertex Pharmaceuticals Incorporated · home listing NASDAQ:VRTX

Follow Vertex Pharmaceuticals Incorporated into a list and get an email when it puts out news.

Share price · BMV:VRTX

$9,936.00 MXN +11.00 (+0.1%)

Close on Nov 20, 2026

Past year +26.4% · daily closes, Nov 20, 2025 – Nov 12, 2026, adjusted for splits
Day range
$9,936.00 – $9,936.00 MXNNov 20, 2026
Volume
52 sharesNov 20, 2026
Market cap
$2.52T MXNAt the close on Nov 20, 2026 · price × 253.8M shares outstanding
52-week range
$7,300.00 – $10,240.00 MXNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.18M MXNMedian day 0 shares · 31 days with no trades · last 3 months, Aug 20, 2026 – Nov 12, 2026
Vertex Pharmaceuticals Incorporated logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VRTX · Home$515.02 USD-21.43 (-4.0%)1,767,642$529.94$531.37$513.80$536.45Close on Nov 20, 2026
BMV:VRTX$9,936.00 MXN+11.00 (+0.1%)52$9,936.00$9,936.00$9,936.00$9,925.00Close on Nov 20, 2026
B3:VRTX3496.41 BRL-1.91 (-1.9%)64698.7098.7096.3198.32Close on Nov 19, 2026
LSE:0QZU$520.00 USD-1.59 (-0.3%)1,492$520.30$537.99$510.00$521.59Close on Nov 20, 2026
Frankfurt:VX1€477.05 EUR-2.95 (-0.6%)149€469.40€477.75€469.40€480.00Close on Nov 20, 2026
Dusseldorf:VX1€474.10 EUR-1.20 (-0.3%)—€473.50€477.85€473.50€475.30Close on Nov 20, 2026
Munich:VX1€474.00 EUR-16.80 (-3.4%)—€479.00€479.00€474.00€490.80Close on Nov 20, 2026
Hamburg:VX1€477.45 EUR+0.75 (+0.2%)—€474.00€477.45€474.00€476.70Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 12, 2026 · BMV:VRTX · MXN, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10,240.000.000.0%$10,240.00$10,240.00$10,240.000
$10,240.000.000.0%$10,240.00$10,240.00$10,240.000
$10,240.00+179.37+1.8%$10,240.00$10,240.00$10,240.005
$10,060.630.000.0%$10,060.63$10,060.63$10,060.630
$10,060.630.000.0%$10,060.63$10,060.63$10,060.630
$10,060.630.000.0%$10,060.63$10,060.63$10,060.630
$10,060.630.000.0%$10,060.63$10,060.63$10,060.630
$10,060.63-69.37-0.7%$10,060.63$10,060.63$10,060.63230
$10,130.000.000.0%$10,130.00$10,130.00$10,130.000
$10,130.00+190.00+1.9%$10,130.00$10,130.00$10,130.005
$9,940.00-92.00-0.9%$9,940.00$9,940.00$9,940.0010
$10,032.000.000.0%$10,032.00$10,032.00$10,032.000
$10,032.000.000.0%$10,032.00$10,032.00$10,032.000
$10,032.000.000.0%$10,032.00$10,032.00$10,032.000
$10,032.00+665.51+7.1%$10,032.00$10,032.00$10,032.008
$9,366.490.000.0%$9,366.49$9,366.49$9,366.490
$9,366.49-133.51-1.4%$9,366.49$9,366.49$9,366.4919
$9,500.000.000.0%$9,500.00$9,500.00$9,500.000
$9,500.000.000.0%$9,500.00$9,500.00$9,500.000
$9,500.00+504.00+5.6%$9,500.00$9,500.00$9,500.00682
$8,996.000.000.0%$8,996.00$8,996.00$8,996.000
$8,996.00-263.00-2.8%$8,996.00$8,996.00$8,996.007
$9,259.00+134.00+1.5%$9,259.00$9,259.00$9,259.0089
$9,125.000.000.0%$9,125.00$9,125.00$9,125.000
$9,125.00+100.00+1.1%$9,125.00$9,125.00$9,125.005
$9,025.000.000.0%$9,025.00$9,025.00$9,025.000
$9,025.00-330.00-3.5%$9,025.00$9,025.00$9,025.0030
$9,355.000.000.0%$9,355.00$9,355.00$9,355.000
$9,355.000.000.0%$9,355.00$9,355.00$9,355.000
$9,355.00-122.64-1.3%$9,355.00$9,355.00$9,355.0019
$9,477.64+235.64+2.5%$9,477.64$9,477.64$9,477.641,092
$9,242.000.000.0%$9,242.00$9,242.00$9,242.000
$9,242.000.000.0%$9,242.00$9,242.00$9,242.000
$9,242.000.000.0%$9,242.00$9,242.00$9,242.000
$9,242.00+307.00+3.4%$9,242.00$9,242.00$9,242.0029
$8,935.00-65.78-0.7%$8,945.37$8,945.37$8,935.0027
$9,000.78+216.35+2.5%$9,000.78$9,000.78$9,000.782,959
$8,784.430.000.0%$8,784.43$8,784.43$8,784.430
$8,784.43+8.069+0.1%$8,784.43$8,784.43$8,784.43632
$8,776.360.000.0%$8,776.36$8,776.36$8,776.360
$8,776.360.000.0%$8,776.36$8,776.36$8,776.360
$8,776.360.000.0%$8,776.36$8,776.36$8,776.360
$8,776.360.000.0%$8,776.36$8,776.36$8,776.360
$8,776.36-46.64-0.5%$8,776.36$8,776.36$8,776.36134
$8,823.00-140.36-1.6%$8,790.00$8,823.00$8,790.00161
$8,963.36-301.64-3.3%$8,963.36$8,963.36$8,963.36615
$9,265.000.000.0%$9,265.00$9,265.00$9,265.000
$9,265.00-199.81-2.1%$9,265.00$9,265.00$9,265.0013
$9,464.81+79.81+0.9%$9,464.81$9,464.81$9,464.81312
$9,385.00+78.50+0.8%$9,385.00$9,385.00$9,385.007
$9,306.50+94.50+1.0%$9,326.87$9,326.87$9,306.50273
$9,212.00-103.00-1.1%$9,212.00$9,212.00$9,212.0012
$9,315.000.000.0%$9,315.00$9,315.00$9,315.000
$9,315.00-74.00-0.8%$9,315.00$9,315.00$9,315.007
$9,389.000.000.0%$9,389.00$9,389.00$9,389.000
$9,389.00-21.00-0.2%$9,389.00$9,389.00$9,389.0076
$9,410.000.000.0%$9,410.00$9,410.00$9,410.000
$9,410.000.000.0%$9,410.00$9,410.00$9,410.000
$9,410.00+207.33+2.3%$9,410.00$9,410.00$9,410.00140
Ticker
BMV:VRTX
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BMV
Currency
MXN

What changed lately

Latest news

All Vertex Pharmaceuticals Incorporated news

Vertex Pharmaceuticals Incorporated on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
47 in the last 12 months · 340 in all · newest Nov 4, 2026 · oldest 2005
Calls
32 calls with a replay · 32 with a transcript · latest Nov 2, 2026
Decks
20 decks · latest Oct 23, 2026

Where Vertex Pharmaceuticals Incorporated is listed

ListingExchangeCountryCurrency
NASDAQ:VRTX · Home listingNASDAQUnited StatesUSD
Xetra:VX1XetraGermanyEUR
gettex:VX1gettexGermanyEUR
BCBA:VRTXBCBAArgentinaARS
Tradegate:VX1TradegateGermanyEUR
LS Exchange:882807LS ExchangeGermanyEUR
BMV:VRTX · This pageBMVMexicoMXN
B3:VRTX34B3BrazilBRL
Lang & Schwarz:882807Lang & SchwarzGermanyEUR
LSE:0QZULSEUnited KingdomUSD
Frankfurt:VX1FrankfurtGermanyEUR
EUROTLX:4VRTXEUROTLXItalyEUR
BCBA:VRTXDBCBAArgentinaUSD
Milan:1VRTXMilanItalyEUR
VIE:VRTXViennaAustriaEUR
BIVA:VRTXBIVAMexicoMXN
BOATS:VRTXBOATSUnited StatesUSD
Stuttgart:VX1StuttgartGermanyEUR
Dusseldorf:VX1DusseldorfGermanyEUR
Hanover:VX1HanoverGermanyEUR
Munich:VX1MunichGermanyEUR
BX Swiss:VX1BX SwissSwitzerlandCHF
Aquis:VX1DAquisUnited KingdomEUR
BCBA:VRTXCBCBAArgentinaUSD
Hamburg:VX1HamburgGermanyEUR
Aquis:VX1DAquisUnited KingdomEUR
Turquoise:VRTXNTurquoiseUnited KingdomUSD
BCBA:VRTX.CIBCBAArgentinaARS

Valuation

P/E 32.8× against a median of 18.8×: 9th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$128.8B USD
P/E
32.8×
EV/sales
9.9×
EV/EBITDA
28.4×
Price/book
6.3×
Gross margin
85.5%
Operating margin
33.2%
Net margin
30.7%
Debt to equity
0.2×
Beta vs S&P 500
0.47

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Vertex Pharmaceuticals Incorporated · NASDAQ:VRTXUS$130.6BUS$128.8B32.8×9.9×28.4×6.3×30.7%0.2×0.47
Merck & Company, Inc. · NYSE:MRKUS$329.7BUS$373.8B134×5.5×n/a7.3×3.6%1.2×0.28
Novartis AG · SIX:NOVNUS$287.4BUS$304.7B20.6×n/an/a6.2×n/a0.6×n/a
AstraZeneca PLC · LSE:AZNUS$272.1BUS$298.0B24.6×4.8×14.1×5.3×17.7%0.7×n/a
Pfizer, Inc. · NYSE:PFEUS$156.2BUS$207.8B38.7×3.3×9.6×1.8×6.3%0.7×0.29
Novo Nordisk A/S Class B · OMXCOP:NOVO_BUS$129.4BUS$142.3B7.8×2.9×5.5×4.0×33.9%0.6×n/a
Bristol-Myers Squibb Company · NYSE:BMYUS$120.2BUS$151.3B13.0×3.0×n/a5.1×18.5%1.9×0.26
Sanofi SA · EURONEXT:SANUS$111.7BUS$126.9B14.6×2.3×4.7×1.4×13.9%0.3×n/a
GSK plc · LSE:GSKUS$96.63BUS$123.8B17.0×2.8×9.3×3.9×13.0%1.3×n/a
argenx SE · EURONEXT:ARGXUS$58.86BUS$53.72B22.8×6.5×n/a7.0×31.4%0.0×n/a
Roche Holding Ltd · SIX:ROUS$51.16BUS$77.45B3.3×1.1×2.9×1.3×20.9%1.0×n/a
Median of the othersUS$124.8BUS$146.8B18.8×3.0×7.4×4.6×17.7%0.7×0.28

Forecasts

20 strong buy · 6 buy · 4 hold · 1 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
592.36 USD · Analysts' mean
EPS, year to Dec 2026
18.12 · 25 analysts
Revenue, year to Dec 2026
13.25B · 27 analysts

Team and board

Officers

OfficerRole
Reshma KewalramaniChief Executive Officer and President
Charles WagnerExecutive Vice President and Chief Operating & Financial Officer
Joy LiuExecutive Vice President and Chief Legal Officer
Vertex Pharmaceuticals IncorporatedInvestor Relations
Amit K. SachdevExecutive Vice President, Chief Patient and External Affairs Officer
Carmen BozicExecutive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Duncan McKechnieExecutive Vice President and Chief Commercial Officer
E. Morrey AtkinsonExecutive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
Jasper van GrunsvenExecutive Vice President and Chief Pain and New Product Planning Officer
Mark BunnageExecutive Vice President and Chief Scientific Officer
Nia TatsisExecutive Vice President and Chief Product Affairs Officer
Jeffrey LeidenExecutive Chairman

Board

DirectorRole
Jeffrey LeidenExecutive Chairman
Alan GarberDirector
Bruce SachsDirector
Daniel J. BrennanDirector
Diana McKenzieDirector
Jennifer SchneiderDirector
Lloyd CarneyDirector
Michel LagardeDirector
Nancy ThornberryDirector
Sangeeta N. BhatiaDirector

Events

Calls

CallWhenStatus
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2026 Earnings CallMon, Nov 02, 2026 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2026 Earnings CallMon, Aug 03, 2026 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2026 Earnings CallMon, May 04, 2026 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2025 Earnings CallThu, Feb 12, 2026 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2025 Earnings CallMon, Nov 03, 2025 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2025 Earnings CallMon, Aug 04, 2025 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2025 Earnings CallMon, May 05, 2025 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2024 Earnings CallMon, Feb 10, 2025 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2024 Earnings CallMon, Nov 04, 2024 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2024 Earnings CallThu, Aug 01, 2024 · 4:30 PM ETReplay
All 32 calls
CallWhenStatus
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2024 Earnings CallMon, May 06, 2024 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2023 Earnings CallMon, Feb 05, 2024 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2023 Earnings CallMon, Nov 06, 2023 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2023 Earnings CallTue, Aug 01, 2023 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2023 Earnings CallMon, May 01, 2023 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2022 Earnings CallTue, Feb 07, 2023 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2022 Earnings CallThu, Oct 27, 2022 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2022 Earnings CallThu, May 05, 2022 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2021 Earnings CallWed, Jan 26, 2022 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2021 Earnings CallTue, Nov 02, 2021 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2021 Earnings CallThu, Jul 29, 2021 · 5:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2021 Earnings CallThu, Apr 29, 2021 · 5:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2020 Earnings CallMon, Feb 01, 2021 · 5:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2020 Earnings CallThu, Oct 29, 2020 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2020 Earnings CallThu, Jul 30, 2020 · 5:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2020 Earnings CallWed, Apr 29, 2020 · 5:00 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2019 Earnings CallThu, Jan 30, 2020 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2019 Earnings CallWed, Oct 30, 2019 · 5:00 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2019 Earnings CallWed, Jul 31, 2019 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2019 Earnings CallTue, Apr 30, 2019 · 4:30 PM ETReplay
Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2018 Earnings CallTue, Feb 05, 2019 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 2, 2026 · After close−4.0%
Q2 2026Aug 3, 2026 · After close+1.7%
Q1 2026May 4, 2026 · After close−1.3%
Q4 2025Feb 12, 2026 · After close+5.7%
Q3 2025Nov 3, 2025 · After close−1.0%
Q2 2025Aug 4, 2025 · After close−20.6%
Q1 2025May 5, 2025 · After close−10.0%
Q4 2024Feb 10, 2025 · After close−3.1%
Q3 2024Nov 4, 2024 · After close+5.7%
Q2 2024Aug 1, 2024 · After close−2.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · After close+1.9%
Q4 2023Feb 5, 2024 · After close−3.0%
Q3 2023Nov 6, 2023 · After close−1.9%
Q2 2023Aug 1, 2023 · After close+3.1%
Q1 2023May 1, 2023 · After close+0.3%
Q4 2022Feb 7, 2023 · After close−4.9%
Q3 2022Oct 27, 2022 · After close+9.0%
Q2 2022Aug 4, 2022 · After close+4.8%
Q1 2022May 5, 2022 · After close−4.7%
Q4 2021Jan 26, 2022 · After close+0.7%

Open Events

Decks

DeckKindSlidesDate
American Society of Nephrology Kidney Week 2026Conference23 slidesOct 23, 2026
Q2 2026 Earnings PresentationEarnings21 slidesAug 3, 2026
Merger or Acquisition (July 2026)Merger or acquisition17 slidesJul 6, 2026
Q1 2026 Earnings PresentationEarnings19 slidesMay 4, 2026
J.P. Morgan Healthcare Conference 2026Conference21 slidesJanuary 2026
American Society of Nephrology Kidney Week 2025Conference42 slidesNov 8, 2025
Q3 2025 Earnings PresentationEarnings20 slidesNov 3, 2025
Q1 2025 Earnings PresentationEarnings20 slidesMay 5, 2025
Q4 2024 Earnings PresentationEarnings19 slidesFeb 10, 2025
Q3 2024 Earnings PresentationEarnings21 slidesNov 4, 2024
All 20 decks
DeckKindSlidesDate
Q2 2024 Earnings PresentationEarnings19 slidesAug 1, 2024
Q1 2024 Earnings PresentationEarnings22 slidesMay 6, 2024
Q4 2023 Earnings PresentationEarnings27 slidesFeb 5, 2024
Q3 2023 Earnings PresentationEarnings20 slidesNov 6, 2023
Q2 2023 Earnings PresentationEarnings20 slidesAug 1, 2023
Q1 2023 Earnings PresentationEarnings21 slidesMay 1, 2023
Q4 2022 Earnings PresentationEarnings21 slidesFeb 7, 2023
Q3 2022 Earnings PresentationEarnings18 slidesOct 27, 2022
FY2018 Earnings PresentationEarnings13 slidesFeb 5, 2019
Q4 2017 Earnings PresentationEarnings24 slidesJan 31, 2018

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue12.0B11.0B9.87B8.93B7.57B6.21B4.16B3.05B2.49B1.70B
Cost of revenue1.65B1.53B1.26B1.08B904.2M736.3M547.8M409.5M275.1M210.5M
Gross profit10.3B9.49B8.61B7.85B6.67B5.47B3.62B2.64B2.21B1.49B
Research and development3.91B3.63B3.16B2.54B3.05B1.83B1.75B1.42B1.32B1.05B
Selling, general and administrative1.75B1.46B1.14B944.7M840.1M770.5M658.5M557.6M496.1M432.8M
Operating income4.17B-232.9M3.83B4.31B2.78B2.86B1.20B635.1M123.2M9.94M
Depreciation and amortization209.8M207.2M181.3M148.3M125.6M109.5M106.9M72.4M61.4M61.4M
EBITDA4.38B-25.7M4.01B4.46B2.91B2.97B1.30B707.6M184.6M71.3M
Interest expense13.3M30.6M44.1M54.8M58.2M58.5M72.5M69.3M
Income before tax4.64B248.5M4.38B4.23B2.73B3.12B1.39B600.2M-15.7M-67.4M
Income tax690.0M784.1M760.2M910.4M388.3M405.2M218.1M-1.49B-107.3M16.7M
Net income3.95B-535.6M3.62B3.32B2.34B2.71B1.18B2.10B263.5M-112.1M
Earnings per share, basic15.46-2.0814.0512.979.0910.444.588.241.06-0.46
Earnings per share, diluted15.32-2.0813.8912.829.0110.294.518.091.04-0.46

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.08B4.57B10.4B10.5B6.79B5.99B3.11B2.65B1.67B1.18B
Short-term investments1.52B1.55B849.2M274.5M729.9M670.7M699.0M518.1M423.3M
Receivables2.05B1.61B1.56B1.44B1.14B885.4M633.5M409.7M281.3M200.4M
Inventory1.69B1.21B738.8M460.6M353.1M280.8M167.5M124.4M111.8M77.6M
Current assets11.2B9.60B14.1B13.2B9.56B8.13B4.82B3.84B2.65B1.83B
Property, plant and equipment745.1M812.0M789.4M698.4M
Goodwill1.09B1.09B1.09B1.09B1.00B1.00B1.00B50.4M50.4M50.4M
Total assets25.6B22.5B22.7B18.2B13.4B11.8B8.32B6.25B3.55B2.90B
Accounts payable461.7M413.0M364.9M303.9M195.0M155.1M87.6M111.0M74.0M61.5M
Current liabilities3.86B3.56B3.55B2.74B2.14B1.88B1.33B1.12B807.3M792.5M
Long-term debt0
Total debt0
Total liabilities6.98B6.12B5.15B4.24B3.33B3.06B2.23B1.81B1.50B1.56B
Shareholders' equity18.7B16.4B17.6B13.9B10.1B8.69B6.09B4.44B2.03B1.16B
Shares outstanding254.0M256.9M257.7M257.0M254.5M259.9M259.0M255.2M253.3M248.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations3.63B-492.6M3.54B4.13B2.64B3.25B1.57B1.27B844.9M236.1M
Capital spending-437.6M-297.7M-200.4M-204.7M-235.0M-259.8M-75.4M-95.4M-99.4M-56.6M
Free cash flow3.19B-790.3M3.34B3.93B2.41B2.99B1.49B1.17B745.5M179.5M
Cash from investing-945.4M-3.77B-3.14B-321.1M-340.9M99.4M-1.24B-202.2M-483.3M51.2M
Cash from financing-2.26B-1.49B-562.2M-67.7M-1.48B-505.3M126.8M-71.2M68.4M133.3M
Share buybacks-2.02B-1.18B-427.6M0-1.43B-539.1M-186.0M-350.0M00
Change in cash515.6M-5.80B-139.7M3.71B811.2M2.87B462.4M990.7M435.8M415.9M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
4 · Change in ownershipNov 10, 2026Insider tradeSEC
144 · Notice of proposed saleNov 6, 2026Other filingsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 2, 2026ResultsSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
8-K · Current reportOct 20, 2026Management or board changeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
8-K · Current reportSep 1, 2026Management or board changeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
144 · Notice of proposed saleAug 27, 2026Other filingsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 3, 2026ResultsSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJul 6, 2026Material contractSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 29, 2026Other filingsSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 POSMay 13, 2026Offer documentSEC
S-8 · Registration statement for employee plansMay 13, 2026Offer documentSEC
8-K · Current reportMay 13, 2026Management or board changeSEC
144 · Notice of proposed saleMay 12, 2026Other filingsSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026ResultsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
8-K · Current reportApr 29, 2026Management or board changeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
UPLOAD · Letter from the SECApr 14, 2026Other filingsSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 2, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 2, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 2, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
CORRESP · Letter to the SECApr 1, 2026Other filingsSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
8-K · Current reportMar 31, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
144 · Notice of proposed saleMar 27, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 18, 2026Other filingsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
144 · Notice of proposed saleMar 13, 2026Other filingsSEC
144 · Notice of proposed saleMar 11, 2026Other filingsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
3 · Initial statement of ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
10-K · Annual reportFeb 13, 2026Annual reportSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
8-K · Current reportFeb 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
3 · Initial statement of ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Vertex Pharmaceuticals Incorporated’s releases · as of Oct 31, 2026

Common shares
253,537,674
Fully diluted
253,537,674

Fully diluted

LineSharesAs of
Common shares253,537,674Oct 31, 2026

Share count over time

CountShares
Oct 31, 2026253,537,674

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Capital Group49.2M19.4%US$25.7BSep 30, 2026
Vanguard24.2M9.6%US$12.7BSep 30, 2026
BlackRock23.8M9.4%US$12.4BSep 30, 2026
State Street12M4.7%US$6.29BSep 30, 2026
Invesco8.28M3.3%US$4.33BSep 30, 2026
Franklin Templeton6.16M2.4%US$3.34BSep 30, 2026
Geode Capital6.08M2.4%US$3.17BSep 30, 2026
JPMorgan5.69M2.2%US$3BSep 30, 2026
UBS4.22M1.7%US$2.2BSep 30, 2026
Loomis Sayles & Co L P3.62M1.4%US$1.89BSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Jennison Associates LLC3.57M1.4%US$1.87BSep 30, 2026
Wellington3.36M1.3%US$1.76BSep 30, 2026
Morgan Stanley3.28M1.3%US$1.71BSep 30, 2026
Bank of America3.13M1.2%US$1.64BSep 30, 2026
AllianceBernstein3.01M1.2%US$1.57BSep 30, 2026
Northern Trust2.57M1.0%US$1.34BSep 30, 2026
Victory Capital2.56M1.0%US$1.34BSep 30, 2026
Ameriprise2.26M0.89%US$1.18BSep 30, 2026
Goldman Sachs2.2M0.87%US$1.15BSep 30, 2026
Schwab1.88M0.74%US$981MSep 30, 2026
Legal & General1.84M0.73%US$964MSep 30, 2026
T. Rowe Price1.73M0.68%US$906MSep 30, 2026
DWS1.7M0.67%US$886MSep 30, 2026
BNY1.69M0.67%US$881MSep 30, 2026
Fidelity1.54M0.61%US$806MSep 30, 2026
Amundi1.51M0.60%US$791MSep 30, 2026
BNP Paribas1.35M0.53%US$705MSep 30, 2026
Assenagon Asset Management S.A.1.22M0.48%US$637MSep 30, 2026
Wcm Investment Management, LLC1.2M0.47%US$632MSep 30, 2026
Janus Henderson1.19M0.47%US$622MSep 30, 2026
Dimensional1.15M0.46%US$603MSep 30, 2026
RBC1.09M0.43%US$571MSep 30, 2026
Nuveen1.06M0.42%US$552MSep 30, 2026
Citadel1.03M0.41%US$540MSep 30, 2026
MUFG888K0.35%US$464MSep 30, 2026
Arrowstreet Capital, Limited Partnership883K0.35%US$462MSep 30, 2026
Neuberger Berman Group LLC821K0.32%US$429MSep 30, 2026
Wells Fargo757K0.30%US$396MSep 30, 2026
First Trust702K0.28%US$367MSep 30, 2026
Swiss National Bank694K0.27%US$363MSep 30, 2026
HSBC673K0.27%US$352MSep 30, 2026
American Century655K0.26%US$342MSep 30, 2026
Pictet Asset Management Holding SA641K0.25%US$336MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.594K0.23%US$311MSep 30, 2026
Bellevue Group AG579K0.23%US$302MSep 30, 2026
Millennium568K0.22%US$297MSep 30, 2026
Sun Life558K0.22%US$308MSep 30, 2026
Manufacturers Life Insurance Company, The550K0.22%US$287MSep 30, 2026
CPP Investments546K0.22%US$286MSep 30, 2026
Raymond James Financial Inc544K0.21%US$284MSep 30, 2026

This page holds 50 of 1,763 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Growth Fund of America12.5M4.9%US$5.59BMay 31, 2026
Vanguard Total Stock Market Index Fund8.06M3.2%US$4BJun 30, 2026
Vanguard 500 Index Fund6.58M2.6%US$3.27BJun 30, 2026
Investment Co of America6.27M2.5%US$3.11BJun 30, 2026
American Balanced Fund5.56M2.2%US$2.76BJun 30, 2026
Invesco QQQ Trust, Series 15.39M2.1%US$2.68BJun 30, 2026
AMCAP Fund4.65M1.8%US$2.08BMay 31, 2026
iShares Core S&P 500 ETF3.49M1.4%US$1.73BJun 30, 2026
New Perspective Fund3.37M1.3%US$1.67BJun 30, 2026
Fidelity 500 Index Fund3.25M1.3%US$1.45BMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Growth Index Fund2.78M1.1%US$1.38BJun 30, 2026
Capital World Growth & Income Fund2.34M0.92%US$1.05BMay 31, 2026
Washington Mutual Investors Fund1.98M0.78%US$943MJul 31, 2026
Vanguard Health Care Fund1.89M0.75%US$902MJul 31, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF1.79M0.71%US$891MJun 30, 2026
Putnam Large Cap Value Fund1.67M0.66%US$795MJul 31, 2026
Growth Fund1.64M0.65%US$815MJun 30, 2026
New Economy Fund1.62M0.64%US$724MMay 31, 2026
iShares Biotechnology ETF1.48M0.58%US$734MJun 30, 2026
Growth-Income Fund1.46M0.58%US$728MJun 30, 2026
Vanguard Institutional Index Fund1.38M0.54%US$684MJun 30, 2026
JPMorgan Equity Premium Income ETF1.32M0.52%US$655MJun 30, 2026
American Funds Fundamental Investors1.17M0.46%US$583MJun 30, 2026
Invesco NASDAQ 100 ETF1.08M0.43%US$483MMay 31, 2026
Loomis Sayles Growth Fund1.03M0.40%US$509MJun 30, 2026
Capital Group Growth ETF847K0.33%US$379MMay 31, 2026
American Funds Global Balanced Fund782K0.31%US$373MJul 31, 2026
Vanguard Health Care Index Fund762K0.30%US$341MMay 31, 2026
iShares MSCI USA Min Vol Factor ETF722K0.28%US$345MJul 31, 2026
Harbor Capital Appreciation Fund706K0.28%US$337MJul 31, 2026
Asset Allocation Fund654K0.26%US$325MJun 30, 2026
Capital Group Dividend Value ETF631K0.25%US$282MMay 31, 2026
State Street(R) SPDR(R) Portfolio S&P 500(R) ETF605K0.24%US$301MJun 30, 2026
iShares Russell 1000 Value ETF568K0.22%US$282MJun 30, 2026
Schwab S&P 500 Index Fund567K0.22%US$270MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.548K0.22%US$272MJun 30, 2026
Schwab U.S. Large-Cap Growth ETF542K0.21%US$243MMay 31, 2026
JPMorgan U.S. Equity Fund502K0.20%US$249MJun 30, 2026
Columbia Contrarian Core Fund492K0.19%US$220MMay 31, 2026
AB Large Cap Growth Fund Inc486K0.19%US$241MJun 30, 2026
JPMorgan Nasdaq Equity Premium Income ETF483K0.19%US$240MJun 30, 2026
Fidelity Total Market Index Fund481K0.19%US$215MMay 31, 2026
Invesco American Franchise Fund435K0.17%US$194MMay 31, 2026
ClearBridge Large Cap Growth Fund434K0.17%US$194MMay 29, 2026
Invesco S&P 500 Equal Weight ETF428K0.17%US$204MJul 31, 2026
Strategic Advisers U.S. Total Stock Fund425K0.17%US$190MMay 31, 2026
ClearBridge Growth Fund422K0.17%US$189MMay 29, 2026
Victory Pioneer Fund422K0.17%US$210MJun 30, 2026
Vanguard Russell 1000 Growth Index Fund419K0.17%US$188MMay 31, 2026
iShares S&P 500 Value ETF418K0.16%US$207MJun 30, 2026

This page holds 50 of 1,068 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Bhatia Sangeeta N.
Director
Sale271USD 547.86US$148KNov 16, 2026
Thornberry Nancy
Director
Sale1,000USD 547.86US$548KNov 16, 2026
Wagner Charles F Jr
Officer: EVP, CO & FO
Sale15,286USD 547.87US$8.37MNov 12, 2026
Kewalramani Reshma
Director, Officer: CEO & President
Sale11,866USD 531.53US$6.31MNov 6, 2026
McKechnie Duncan
Officer: EVP, Chief Commercial Officer
Sale1,541USD 519.00US$800KJul 2, 2026
Tatsis Ourania
Officer: EVP, Chief Reg. & Quality Off.
Sale1,500USD 524.99US$787KJul 2, 2026
Liu Joy
Officer: EVP and Chief Legal Officer
Sale828USD 502.71US$416KJul 1, 2026
Bozic Carmen
Officer: EVP and CMO
Sale596USD 482.50US$288KJun 26, 2026
Bozic Carmen
Officer: EVP and CMO
Sale1,020USD 462.17US$471KJun 18, 2026
Bozic Carmen
Officer: EVP and CMO
Sale4,062USD 450.00US$1.83MJun 15, 2026
All 19 trades
TradeTradeSharesPriceValueDate
Bozic Carmen
Officer: EVP and CMO
Sale1,745USD 450.00US$785KJun 5, 2026
Liu Joy
Officer: EVP and Chief Legal Officer
Sale828USD 439.91US$364KJun 1, 2026
Bozic Carmen
Officer: EVP and CMO
Sale1,974USD 450.00US$888KMay 29, 2026
Bozic Carmen
Officer: EVP and CMO
Sale1,354USD 453.45US$614KMay 15, 2026
Bunnage Mark E.
Officer: EVP, Chief Scientific Officer
Sale33USD 453.45US$14,964May 15, 2026
Bozic Carmen
Officer: EVP and CMO
Sale6,988USD 450.00US$3.14MMay 12, 2026
Bhatia Sangeeta N.
Director
Sale318USD 423.73US$135KMay 4, 2026
Liu Joy
Officer: EVP and Chief Legal Officer
Sale1,104USD 425.02US$469KMay 1, 2026
Liu Joy
Officer: EVP and Chief Legal Officer
Sale978USD 449.17US$439KApr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Capital World Investors10.10%25.7MMar 31, 2026Schedule 13G
Vanguard Capital Management LLC7.49%19MMar 31, 2026Schedule 13G
Capital Research Global Investors7.00%17.8MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
William Young
Other companies: Autolus Therapeutics plc (Chair of the Nominating and Governance Committee, Member of the Research & Development Committee · Since at least Mar 18, 2026); Praxis Precision Medicines, Inc. (Director · Since at least Oct 15, 2020); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 26, 2022 · Past); NanoString Technologies Inc (Director · Jun 25, 2013 – May 6, 2024 · Past); BioMarin Pharmaceutical Inc. (Director · Sep 22, 2010 – Jun 10, 2015 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Apr 27, 2006 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – May 22, 2014 · Past); Biogen Inc. (Director · Jan 9, 2006 – Jan 8, 2014 · Past)
Director · May 7, 2014 – Jun 1, 2020 · Past
Nancy J. Wysenski
Other companies: Cytokinetics, Incorporated (Director · Since at least Nov 20, 2020); Provention Bio Inc (Director · May 19, 2020 – Apr 27, 2023 · Past); Dova Pharmaceuticals Inc (Director · Jun 25, 2018 – Nov 12, 2019 · Past); Inovio Pharmaceuticals, Inc. (Director · Mar 4, 2015 – May 13, 2016 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 10, 2014 – Jun 10, 2019 · Past); Alkermes plc (Director · May 15, 2013 – Jul 7, 2023 · Past); Indevus Pharmaceuticals Inc (Director · Feb 23, 2009 – Feb 23, 2009 · Past); North American Scientific Inc (Director · May 3, 2006 – Apr 29, 2008 · Past)
EVP, Chief Commercial Officer · Dec 9, 2009 – May 14, 2012 · Past
Dennis L Winger
Other companies: Pacira BioSciences, Inc. (Director · Sep 11, 2013 – Jun 14, 2017 · Past); Nektar Therapeutics (Director · Dec 8, 2009 – Aug 17, 2018 · Past); Accuray Incorporated (Director · Sep 4, 2009 – Nov 30, 2017 · Past); Cell Genesys Inc (Director · Jun 30, 2006 – Oct 14, 2009 · Past); Cephalon Inc (Director · May 17, 2006 – Oct 14, 2011 · Past); Heron Therapeutics, Inc. (Director · Mar 20, 2006 – Aug 11, 2006 · Past); Applied Biosystems Inc. (Senior Vice President and CFO · Jan 25, 2006 – Nov 20, 2008 · Past)
Director · Jul 6, 2009 – Mar 9, 2012 · Past
Charles A Sanders
Other companies: LipoScience Inc (Director · Jan 24, 2013 – Jan 30, 2013 · Past); BioCryst Pharmaceuticals, Inc. (Director · Dec 8, 2009 – Feb 29, 2016 · Past); Cephalon Inc (Director · May 12, 2009 – May 20, 2010 · Past); Genentech Inc (Director · Mar 26, 2009 – Mar 26, 2009 · Past); Icagen Inc (Director · Mar 5, 2009 – Sep 2, 2011 · Past); Albireo Pharma Inc (Director · Mar 3, 2009 – Mar 8, 2012 · Past)
Director · May 4, 2009 – Jun 1, 2010 · Past
Stuart Arbuckle
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jan 5, 2026); Rhythm Pharmaceuticals, Inc. (Director · Since at least Jul 23, 2019); ImmunoGen Inc (Director · Jan 23, 2018 – Feb 12, 2024 · Past); Dare Bioscience, Inc. (Director · Jun 22, 2016 – Jan 3, 2017 · Past)
EVP, COO · Since at least May 25, 2016
Christiana Stamoulis
Other companies: Mallinckrodt Inc (President and CFO · Since at least Sep 22, 2025); Incyte Corporation (EVP & Chief Financial Officer · Since at least Feb 11, 2019); Hologic Inc (Director · Since at least Nov 1, 2011); Cogent Biosciences, Inc. (President & C.F.O. · Mar 28, 2018 – Mar 28, 2018 · Past)
SVP, Corp Strategy & Bus Devlp · Oct 6, 2010 – Jul 30, 2013 · Past
Daniel Brennan
Other companies: Crinetics Pharmaceuticals, Inc. (Member of the Board of Directors · Since at least Nov 4, 2026); Madrigal Pharmaceuticals, Inc. (Director · Since at least Aug 1, 2025); Waters Corporation (Director · Since at least Nov 23, 2022); Boston Scientific Corporation (EVP and CFO · Jan 1, 2023 – Feb 18, 2025 · Past)
Director · Since at least Oct 20, 2026
Jeffrey A Chodakewitz
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Apr 13, 2021); Schrodinger, Inc. (Board Member · Since at least Apr 30, 2020); Adicet Bio, Inc. (Director · Since at least Aug 14, 2018); Tetraphase Pharmaceuticals Inc (Director · Jun 12, 2014 – Jun 10, 2019 · Past)
EVP · Jul 15, 2014 – Apr 1, 2018 · Past
Terrence C Kearney
Other companies: AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Innoviva, Inc. (Director · Oct 30, 2014 – Apr 24, 2015 · Past); Acceleron Pharma Inc (Director · Jul 14, 2014 – Nov 19, 2021 · Past); Hospira Inc (Chief Operating Officer · May 17, 2006 – Dec 15, 2010 · Past)
Director · May 17, 2011 – May 1, 2024 · Past
Wayne Riley
Other companies: Heartflow, Inc. (Member of the Board of Directors · Since at least Aug 7, 2025); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); HCA Healthcare, Inc. (Director · Since at least Jan 1, 2012); Pinnacle Financial Partners, Inc. (Director · Feb 28, 2011 – Feb 28, 2013 · Past)
Director · Jul 9, 2010 – Jun 1, 2015 · Past
All 58 people
PersonSeat
Diana L. McKenzie
Other companies: Agilon Health, Inc. (Director · Since at least Feb 17, 2023); MetLife, Inc. (Director · Since at least Apr 1, 2022); Change Healthcare Inc (Director · Apr 25, 2022 – Oct 3, 2022 · Past)
Director · Since at least Apr 14, 2022
Elaine Ullian
Other companies: Hologic Inc (Director · Oct 22, 2007 – Nov 13, 2017 · Past); Valeant Pharmaceuticals International Inc (Director · Jan 1, 2006 – Jan 1, 2008 · Past); Thermo Fisher Scientific Inc (Director · Dec 31, 2005 – May 22, 2019 · Past)
Director · Jun 1, 2006 – Jun 1, 2019 · Past
Eve Elizabeth Slater
Other companies: Aceragen Inc. (Director · Jun 16, 2010 – Jun 8, 2015 · Past); Phase Forward Inc (Director · Feb 26, 2007 – Feb 26, 2007 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 25, 2007 · Past)
Director · Mar 23, 2006 – Jun 1, 2007 · Past
Jeffrey Leiden
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Quest Diagnostics Incorporated (Director · Jul 1, 2015 – May 29, 2018 · Past)
Executive Chairman · Since at least Jul 21, 2015
Jennifer Schneider
Other companies: Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Health Assurance Acquisition Corp (Director · Nov 12, 2020 – Nov 12, 2020 · Past); Livongo Health Inc (President · Jul 24, 2019 – Oct 30, 2020 · Past)
Director · Since at least May 15, 2024
Margaret G McGlynn
Other companies: Novavax, Inc. (Director · Since at least Dec 7, 2020); Amicus Therapeutics Inc (Director · Since at least Oct 28, 2009); Air Products and Chemicals, Inc. (Director · Dec 31, 2005 – Sep 30, 2020 · Past)
Director · May 12, 2011 – May 1, 2023 · Past
Michel Lagarde
Other companies: West Pharmaceutical Services, Inc. (be President and Chief Executive Officer · Since at least Jun 1, 2026); Thermo Fisher Scientific Inc (Executive Vice President · Since at least Aug 29, 2017); Patheon N.V. (President · Jul 20, 2016 – Aug 29, 2017 · Past)
Director · Since at least Oct 5, 2023
David T Howton
Other companies: Solid Biosciences Inc. (Chief Operating Officer · Since at least Dec 2, 2022); Sarepta Therapeutics, Inc. (EVP, General Counsel · Nov 5, 2012 – Jun 22, 2020 · Past)
SVP & Chief Legal Officer · Aug 29, 2011 – Feb 2, 2012 · Past
John Alam
Other companies: CervoMed Inc. (Co-Founder and Chief Executive Officer · Since at least Aug 16, 2023); Pathfinder Cell Therapy Inc (Director · Sep 2, 2011 – Sep 2, 2011 · Past)
EVP, Med. Dev. Group & CMO · Dec 20, 2005 – Oct 1, 2008 · Past
Jonathan Biller
Other companies: Agios Pharmaceuticals, Inc. (Chief Financial Officer · Dec 3, 2019 – Mar 1, 2022 · Past); Celgene Corporation (EVP AND GENERAL COUNSEL · Jul 3, 2018 – Nov 20, 2019 · Past)
EVP and Chief Legal Officer · Since at least Sep 19, 2022
Lloyd Carney
Other companies: Visa Inc. (Director · Since at least Jan 23, 2024); Grid Dynamics Holdings, Inc. (Director · Since at least Nov 14, 2023)
Director · Since at least May 1, 2024
Matthew Emmens
Other companies: Bristol-Myers Squibb Company (Director · Feb 21, 2017 – Mar 31, 2021 · Past); Incyte Corporation (Director · May 23, 2006 – May 22, 2008 · Past)
Director · Jun 1, 2006 – Jun 1, 2012 · Past
Nancy A. Thornberry
Other companies: Denali Therapeutics Inc. (Director · Since at least Jan 8, 2021); Schrodinger, Inc. (Board Member · Since at least Feb 5, 2020)
Director · Since at least Dec 5, 2023
Ourania Tatsis
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Verve Therapeutics Inc (Director · Since at least Jun 26, 2024)
EVP, Chief Reg. & Quality Off. · Since at least Oct 1, 2019
Paul M Silva
Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Nurix Therapeutics, Inc. (Director · Since at least Oct 1, 2021)
SVP & Chief Accounting Officer · Sep 29, 2008 – Feb 26, 2021 · Past
Suketu Upadhyay
Other companies: Incyte Corporation (EVP & Chief Financial Officer · Since at least May 4, 2026); Zimmer Biomet Holdings, Inc. (Exec VP, CFO · Since at least Feb 25, 2021)
Director · Since at least May 18, 2022
Alan Garber
Other companies: Exelixis, Inc. (Director · May 2, 2006 – Mar 21, 2024 · Past)
Director · Since at least Jun 8, 2017
Amit K. Sachdev
Other companies: Eiger Biopharmaceuticals Inc (Director · Apr 15, 2019 – Mar 1, 2023 · Past)
Executive Vice President, Chief Patient and External Affairs Officer · Since at least Jul 23, 2007
Bastiano Sanna
Other companies: Adicet Bio, Inc. (Director · Dec 1, 2020 – Aug 14, 2023 · Past)
EVP, Cell & Genetic Therapies · Feb 3, 2021 – May 5, 2023 · Past
Charles F Wagner Jr
Other companies: TJX Companies, Inc. (the) (Director · Since at least Sep 20, 2023)
EVP, CO & FO · Since at least Apr 1, 2022
Edward Morrow Atkinson III
Other companies: 89bio Inc (Director · Since at least Feb 17, 2022)
EVP, Chief Technical Ops. Off. · Since at least Aug 29, 2023
Joshua Boger
Other companies: CervoMed Inc. (Chair Of The Board · Since at least Feb 7, 2024)
Director · Feb 2, 2006 – Jun 8, 2017 · Past
Kenneth L Horton
Other companies: Senseonics Holdings, Inc. (GC & Corp. Development Advisor · Since at least Mar 5, 2021)
EVP & Chief Legal Officer · Jun 11, 2012 – Nov 17, 2014 · Past
Lisa Kelly
Other companies: Nitromed Inc (V.P., Human Resources · Jan 6, 2006 – Mar 30, 2006 · Past)
SVP, Human Resources · Jul 12, 2007 – Feb 5, 2013 · Past
Michael Parini
Other companies: Biogen Inc. (Chief Legal Officer · Since at least Jul 15, 2026)
EVP, Chief Adm, Leg & BD Off · Jan 4, 2016 – Feb 24, 2021 · Past
Reshma Kewalramani
Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past)
Chief Executive Officer and President · Since at least Apr 1, 2018
Susie Lisa
Other companies: Crinetics Pharmaceuticals, Inc. (Senior Vice President, Investor Relations · Since at least Nov 4, 2026)
Investor Relations · May 5, 2025 – Nov 4, 2026 · Past
Yuchun Lee
Other companies: Unica Corp (President, CEO & Chairman, Director · Sep 6, 2006 – Sep 29, 2010 · Past)
Director · Sep 14, 2012 – May 1, 2023 · Past
Antoinette PaoneChief Development Officer and Head of Regulatory Affairs · Jan 29, 2026 – Nov 5, 2026 · Past
Bruce SachsDirector · Since at least Apr 14, 2022
Carmen BozicExecutive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer · Since at least Oct 1, 2019
Charles WagnerExecutive Vice President and Chief Operating & Financial Officer · Since at least Sep 1, 2026
David AltshulerEVP, Chief Scientific Officer · Since at least May 23, 2012
Duncan McKechnieExecutive Vice President and Chief Commercial Officer · Since at least Jul 1, 2025
E. Morrey AtkinsonExecutive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations · Since at least Nov 5, 2026
Eugene CordesDirector · Jun 1, 2009 – Mar 17, 2011 · Past
Jasper van GrunsvenExecutive Vice President and Chief Pain and New Product Planning Officer · Since at least Sep 1, 2026
Joy LiuExecutive Vice President and Chief Legal Officer · Since at least Mar 2, 2021
Kristen AmbroseSVP & Chief Accounting Officer · Since at least May 1, 2021
Mark BunnageExecutive Vice President and Chief Scientific Officer · Since at least Aug 4, 2025
Megan E PaceSVP, Corp. Communications · Jul 25, 2012 – Nov 17, 2014 · Past
Nia TatsisExecutive Vice President and Chief Product Affairs Officer · Since at least Oct 9, 2025
Richard C GarrisonSVP and Catalyst · Feb 2, 2006 – May 18, 2009 · Past
Roger W BrimblecombeDirector · Feb 13, 2006 – Mar 15, 2010 · Past
Sangeeta N. BhatiaDirector · Since at least Jun 4, 2015
Thomas ConnollySVP, Human Resources · Aug 13, 2013 – Dec 12, 2014 · Past
Vertex Pharmaceuticals IncorporatedInvestor Relations · Since at least Apr 6, 2026
Victor A HartmannEVP, Strategic & Corp. Devlp. · Feb 2, 2006 – Jun 4, 2007 · Past

Open People

Log in to ask 6ix AI your own questions about Vertex Pharmaceuticals Incorporated.